
Isomorphic Labs in early talks to raise at up to $50bn, almost triple its $17.5bn valuation five months ago
London drug discovery company Isomorphic Labs is in early discussions to raise new capital at a valuation of at least $40bn and as much as $50bn (£37bn), according to Bloomberg. The Google DeepMind spinout was valued at roughly $17.5bn when it closed a $2.1bn Series B in May.













